
    
      A double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose
      phase II study to investigate the local and systemic effects of inhaled AZD8683 in patients
      with chronic obstructive pulmonary disease (COPD)
    
  